Grant E, Gras S
Clin Transl Immunology. 2024; 13(11):e70017.
PMID: 39584190
PMC: 11583075.
DOI: 10.1002/cti2.70017.
Cui X, Vervaeke P, Gao Y, Opsomer L, Sun Q, Snoeck J
NPJ Vaccines. 2024; 9(1):138.
PMID: 39097672
PMC: 11298010.
DOI: 10.1038/s41541-024-00932-x.
Amoah S, Cao W, Sayedahmed E, Wang Y, Kumar A, Mishina M
J Virol. 2024; 98(8):e0071124.
PMID: 39082839
PMC: 11334528.
DOI: 10.1128/jvi.00711-24.
Mosmann T, McMichael A, LeVert A, McCauley J, Almond J
Nat Rev Immunol. 2024; 24(10):736-752.
PMID: 38698082
DOI: 10.1038/s41577-024-01030-8.
Yuan F, Schieber T, Stein T, Sestak R, Olson C, Chen C
Vaccines (Basel). 2023; 11(3).
PMID: 36992230
PMC: 10056052.
DOI: 10.3390/vaccines11030646.
Protein Nanoparticle-Mediated Delivery of Recombinant Influenza Hemagglutinin Enhances Immunogenicity and Breadth of the Antibody Response.
Badten A, Ramirez A, Hernandez-Davies J, Albin T, Jain A, Nakajima R
ACS Infect Dis. 2023; 9(2):239-252.
PMID: 36607269
PMC: 9926493.
DOI: 10.1021/acsinfecdis.2c00362.
Understanding the Role of HLA Class I Molecules in the Immune Response to Influenza Infection and Rational Design of a Peptide-Based Vaccine.
Muraduzzaman A, Illing P, Mifsud N, Purcell A
Viruses. 2022; 14(11).
PMID: 36423187
PMC: 9695287.
DOI: 10.3390/v14112578.
Human Innate Lymphoid Cells in Influenza Infection and Vaccination.
Kumar A, Kumari R, Liu T, Cao W, Davidson B, Knight P
Crit Rev Immunol. 2022; 41(3):57-82.
PMID: 35378011
PMC: 9185163.
DOI: 10.1615/CritRevImmunol.2021040801.
The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge.
Utrilla-Trigo S, Jimenez-Cabello L, Calvo-Pinilla E, Marin-Lopez A, Lorenzo G, Sanchez-Cordon P
J Virol. 2021; 96(3):e0161421.
PMID: 34787454
PMC: 8826911.
DOI: 10.1128/JVI.01614-21.
A Continuous Model of Three Scenarios of the Infection Process with Delayed Immune Response Factors.
Perevaryukha A
Biophysics (Oxf). 2021; 66(2):327-348.
PMID: 34230672
PMC: 8252696.
DOI: 10.1134/S0006350921020160.
Association of Clinical and Immunological Characteristics With Disease Severity and Outcomes in 211 Patients With COVID-19 in Wuhan, China.
Wang M, Fan Y, Chai Y, Cheng W, Wang K, Cao J
Front Cell Infect Microbiol. 2021; 11:667487.
PMID: 34123873
PMC: 8195246.
DOI: 10.3389/fcimb.2021.667487.
Selecting and Using the Appropriate Influenza Vaccine for Each Individual.
Sekiya T, Ohno M, Nomura N, Handabile C, Shingai M, Jackson D
Viruses. 2021; 13(6).
PMID: 34073843
PMC: 8225103.
DOI: 10.3390/v13060971.
Systems Immunology: Revealing Influenza Immunological Imprint.
Tomic A, Pollard A, Davis M
Viruses. 2021; 13(5).
PMID: 34065617
PMC: 8160800.
DOI: 10.3390/v13050948.
Structural basis of Blastomyces Endoglucanase-2 adjuvancy in anti-fungal and -viral immunity.
Dos Santos Dias L, Dobson H, Bakke B, Kujoth G, Huang J, Kohn E
PLoS Pathog. 2021; 17(3):e1009324.
PMID: 33735218
PMC: 8009368.
DOI: 10.1371/journal.ppat.1009324.
T Cell Immunity against Influenza: The Long Way from Animal Models Towards a Real-Life Universal Flu Vaccine.
Schmidt A, Lapuente D
Viruses. 2021; 13(2).
PMID: 33525620
PMC: 7911237.
DOI: 10.3390/v13020199.
Impaired Cellular Immune Responses During the First Week of Severe Acute Influenza Infection.
Turner J, Lei T, Schmitz A, Day A, Choreno-Parra J, Jimenez-Alvarez L
J Infect Dis. 2020; 222(7):1235-1244.
PMID: 32369589
PMC: 7768688.
DOI: 10.1093/infdis/jiaa226.
Cutaneous Dengue Virus Inoculation Triggers Strong B Cell Reactions but Contrastingly Poor T Cell Responses.
Marcial-Juarez E, Garcia-Cordero J, Maqueda-Alfaro R, Saucedo-Lopez R, Enid Sanchez-Torres L, Cedillo-Barron L
Virol Sin. 2020; 35(5):575-587.
PMID: 32314276
PMC: 7168571.
DOI: 10.1007/s12250-020-00213-6.
Protein Kinase C-η Deficiency Does Not Impair Antiviral Immunity and CD8 T Cell Activation.
Liu H, Pedros C, Kong K, Canonigo-Balancio A, Altman A
J Immunol. 2020; 204(9):2439-2446.
PMID: 32198145
PMC: 7373375.
DOI: 10.4049/jimmunol.1900963.
Efficacy of FLU-v, a broad-spectrum influenza vaccine, in a randomized phase IIb human influenza challenge study.
Pleguezuelos O, James E, Fernandez A, Lopes V, Rosas L, Cervantes-Medina A
NPJ Vaccines. 2020; 5(1):22.
PMID: 32194999
PMC: 7069936.
DOI: 10.1038/s41541-020-0174-9.
Broadly Protective Strategies Against Influenza Viruses: Universal Vaccines and Therapeutics.
Vogel O, Manicassamy B
Front Microbiol. 2020; 11:135.
PMID: 32117155
PMC: 7020694.
DOI: 10.3389/fmicb.2020.00135.
